

PRODUCT INFORMATION




Cenerimod

Item No. 29665

CAS Registry No.: 1262414-04-9
Formal Name: (2S)-3-[4-[5-(2-cyclopentyl-6-methoxy-4-pyridinyl)-1,2,4-oxadiazol-3-yl]-2-ethyl-6-methylphenoxy]-1,2-propanediol

MF: C₂₅H₃₁N₃O₅
FW: 453.5
Purity: ≥95%
UV/Vis.: λ_{max}: 249 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Cenerimod is supplied as a crystalline solid. A stock solution may be made by dissolving the cenerimod in the solvent of choice, which should be purged with an inert gas. Cenerimod is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of cenerimod in these solvents is approximately 10, 20, and 25 mg/ml, respectively.

Cenerimod is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, cenerimod should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Cenerimod has a solubility of approximately 0.3 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Cenerimod is a sphingosine-1-phosphate receptor 1 (S1P₁) modulator with an EC₅₀ value of 1 nM in a [³⁵S]GTPγS binding assay.¹ It is selective for S1P₁ over S1P₂, -3, -4, and -5 (EC₅₀s = >10,000, 228, 2,137, and 36 nM, respectively). Cenerimod (5 μM) decreases TGF-β-induced increases in collagen levels in primary mouse skin fibroblasts.² It inhibits CD4⁺ T cell, CD8⁺ T cell, and CD11b⁺ cell infiltration, reduces *Il1b*, *Il6*, and *Il13* expression, as well as decreases fibrosis in the skin of a mouse model of sclerodermatous chronic graft versus host disease induced by allogenic bone marrow transplant when administered at a dose of 10 mg/kg per day. Cenerimod (6 mg/kg per day for 32 days) reduces paralysis and spinal cord demyelination in a mouse model of experimental autoimmune encephalitis (EAE).

References

1. Piali, L., Birker-Robaczewska, M., Lescop, C., *et al.* Cenerimod, a novel selective S1P₁ receptor modulator with unique signaling properties. *Pharmacol. Res. Perspec.* **5(6)**, e00370 (2017).
2. Kano, M., Kobayashi, T., Date, M., *et al.* Attenuation of murine sclerodermatous models by the selective S1P₁ receptor modulator cenerimod. *Sci. Rep.* **9(1)**, 658 (2019).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/06/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM